已经证明了使用甲硅烷基硼酸盐和 B 2 pin 2通过吡啶介导的 B 元素间活化对烯烃进行无金属甲硅烷基吡啶基化,这为各种 C 4甲硅烷基烷基化吡啶提供了实用的策略。DFT 计算和控制实验表明,反应通过甲硅烷基自由基加成/自由基-自由基偶联顺序进行。该协议具有广泛的底物范围和优异的官能团兼容性,因此在生物活性分子的后期修饰中展示了巨大的潜力。
A radical-mediated oxidative cross-coupling of readily accessible α-alkylated styrenes with 1,3-dicarbonyl compounds utilizing a combination of Cu(OAc)2 and air as a catalytic system is described. Rather than requiring α-halocarbonyl compounds, this efficient approach enables direct installation of tertiary functionalized alkyl motifs to olefins with simple carbonyl derivatives. The novel protocol
The present provides a condensed pyridine compound (I) represented by the following formula:
(wherein, R2 represents
ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and
B represents
its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.
Perfluoroalkylative pyridylation of alkenes<i>via</i>4-cyanopyridine-boryl radicals
作者:Jia Cao、Guoqiang Wang、Liuzhou Gao、Hui Chen、Xueting Liu、Xu Cheng、Shuhua Li
DOI:10.1039/c8sc05237a
日期:——
developed via a combination of computational and experimental studies. Density functional theory calculations and control experiments indicate that the homolysis of Rf−X (X = Br, I) bonds by the 4-cyanopyridine-boryl radicals in situ generated from 4-cyanopyridine and B2pin2 is the key step. Sequential addition of Rf radicals to alkenes and the selective cross-coupling of the resulting alkyl radicals and
Certain 1,3-disubstituted isoquinoline derivatives
申请人:Eisai Co., Ltd.
公开号:US20040204421A1
公开(公告)日:2004-10-14
Condensed pyridine compounds represented by formula (I):
1
wherein: R
1
and R
3
are, independently, hydrogen, halogen, lower alkyl, or lower alkoxy; R
2
represents an amino substituent; ring A is a benzene ring, pyridine ring, thiophene ring, or furan ring; and B represents a substituent containing a ring structure. Also, pharmaceutically acceptable salt and hydrates thereof. These compounds are clinically useful medicaments having serotonin antagonism, and in particular, for treating, ameliorating, or preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.